Home > Oncology > ASCO 2021 > Basic Science > CYT-0851 shows promising anti-tumour activity across different tumour types

CYT-0851 shows promising anti-tumour activity across different tumour types

Presented By
Dr Ryan Lynch, Fred Hutchinson Cancer Research Center, WA, USA
Conference
ASCO 2021
Trial
Phase 1/2
CYT-0851 is the first DNA-damage repair therapeutic with demonstrated clinical activity in both haematologic malignancies and solid tumours, as results from a phase 1-2 trial showed. Homologous recombination is an essential, high-fidelity mechanism to repair DNA double-strand breaks. Overexpression of the cytidine deaminase family of DNA damaging enzymes in subsets of cancers leads to increased DNA damage and subsequent dependence on homologous recombination-mediated DNA repair. Inhibition of homologous recombination in cancer cells leads to accumulation of unrepaired DNA double-strand breaks and tumour cell death. RAD51 is a key enzyme involved in homologous recombination. CYT-0851 is an oral, first-in-class, small-molecule inhibitor of RAD51-mediated DNA repair. Previously, CYT-0851 showed anticancer activity in preclinical models of solid and haematological cancer [1,2]. Dr Ryan Lynch (Fred Hutchinson Cancer Research Center, WA, USA) presented t...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on